Evaluation of IBI302 Injection in nAMD or DME

Inclusion criteria 1. Willing and able to sign informed consent form and comply with visit and study procedures per protocol; 2. Male or female patiensubjects ≥ 18 yrs. of age; 3. For AMD subjects, active subfoveal or parafoveal CNV secondary to neovascular AMD; the vision decreased by nAMD; 4. For DME subjects, Type 1 or type 2 diabetes mellitus, decrease in vision determined to be primarily the result of DME in the study eye; the CST measurement of ≥ 280 μm in the study eye; 5. BCVA ETDRS letter score of 24-73 in the study eye; Exclusion criteria 1. Concomitant diseases that may cause subjects fail to respond to the treatment or confuse the interpretation of the study results; 2. Presence of uncontrolled glaucoma in the study eye ; 3. Presence of active intraocular or periocular inflammation or infection; 4. Prior any treatment of following in the study eye: 1. Anti-VEGF therapy or anti-complement therapy; 2. Laser photocoagulation; 3. History of vitreoretinal surgery; 4. Glucocorticoid treatment(intravitreal or peribulbar) ; 5. BCVA score \<19 letters in the fellow eye; 6. Anti-VEGF therapy in the fellow eye within 30 days of day 0; 7. Presence of any systemic disease: including but not limited to active infections (such as active viral hepatitis); unstable angina; cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening; serious arrhythmia requiring medical treatment; liver, kidney or metabolic diseases; uncontrolled clinical disease(such as diabetes mellitus, hypertension) or malignant tumor; 8. History of severe hypersensitivity/allergy to active ingredients or any excipients of the study drug, or fluorescein and povidone iodine; 9. Pregnant or lactating women or women preparing to become pregnant or breastfeeding during the study period; 10. Participated in any clinical study of any other drug within 90 days of day 0, or attempted to participate in other drug trials during the study; 11. Other conditions unsuitable for enrollment judged by investigatiors.